Pre-eclampsia primary prevention

Pre-eclampsia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pre-eclampsia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pre-eclampsia primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pre-eclampsia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pre-eclampsia primary prevention
CDC on Pre-eclampsia primary prevention
Pre-eclampsia primary prevention in the news
Blogs on Pre-eclampsia primary prevention
Directions to Hospitals Treating Pre-eclampsia
Risk calculators and risk factors for Pre-eclampsia primary prevention

the need for its prevention emerges. It has already been demonstrated by a meta-analysis that early use (before the 16th week of pregnancy) of low-dose aspirin reduces the occurrence of preeclampsia, especially in itsmore severe forms (before 34 weeks) [45]. A recent clinical trial involving about 2,000 pregnant women compared aspirin and placebo use and observed a 62% reduction in the occurrence of early preeclampsia, in the group that daily took 150 mg aspirin [46]. Metformin